Menu Close

Trending

AbbVie and Cugene partner to tackle autoimmune diseases
2nd Annual mRNA-Based Therapeutics Summit
BenevolentAI, AstraZeneca AI-based drug discovery collaboration achieves third milestone
Do pharmaceutical businesses need to rethink what their graduate schemes offer?
AstraZeneca extends oncology partnership with Proteros

ASCO-contributor

Kantar_ASCO Day 5 coverage pic

ASCO-contributor/ Oncology/ Partner content/ Partner Content/ Pharma Market Access/ Press releases

Ibrance approval cemented as competition comes into view

, , , , , 0 Comment

In February 2015,  Pfizer’s Ibrance (palbociclib) was granted accelerated approval by the FDA for treatment of newly diagnosed

X
Ibrance approval cemented as competition comes into view
https://pharmaphorum.com/partner-content-oncology/ibrance-approval-cemented-competition-comes-view/
Kantar_ASCO Day 4 coverage pic

ASCO-contributor/ Market Access/ Oncology/ Partner Content/ Partner content/ Partner Content/ Pharma Market Access/ Press releases

Does NEMO bring us a step closer in the fight against melanoma?

, , , , , , , 0 Comment

Options for treatment in metastatic melanoma have increased significantly in terms of efficacy and reduction of mortality in

X
Does NEMO bring us a step closer in the fight against melanoma?
https://pharmaphorum.com/partner-content-oncology/nemo-bring-us-step-closer-fight-melanoma/
Kantar_ASCO Day 4 coverage pic

ASCO-contributor/ Market Access/ Oncology/ Partner Content/ Partner Content/ Partner content/ Pharma Market Access/ Press releases

The HNSCC immunotherapy race is on – and it’s going to be close

, , , , , , 0 Comment

While improper to compare life saving treatments to buses – the metaphor when it comes to head and

X
The HNSCC immunotherapy race is on – and it’s going to be close
https://pharmaphorum.com/partner-content-oncology/hnscc-immunotherapy-race-going-close/
Kantar_ASCO Day 3 coverage pic

ASCO-contributor/ Market Access/ Oncology/ Partner Content/ Partner Content/ Partner content/ Pharma Market Access/ Press releases

Further Darzalex results extend hope for PFS in Myeloma

, , , , , 0 Comment

Earlier this year (March), Johnson & Johnson announced that the randomized Phase III CASTOR trial (NCT02136134) achieved its

X
Further Darzalex results extend hope for PFS in Myeloma
https://pharmaphorum.com/partner-content-oncology/further-darzalex-results-extend-hope-for-pfs-in-myeloma/
Kantar_ASCO Day 2 coverage pic 1

ASCO-contributor/ Clinical/ Market Access/ Oncology/ Partner content/ Partner Content/ Partner Content/ Pharma Market Access/ Press releases

Positive PIII results for VYXEOS revealed at ASCO

, , , , , , , 0 Comment

Building on the announcement made in March of this year, Celator Pharmaceuticals has today (June 4th) presented the

X
Positive PIII results for VYXEOS revealed at ASCO
https://pharmaphorum.com/partner-content-oncology/positive-piii-results-for-vyxeos-revealed-at-asco/

Login

CONTINUE TO SITE >
X
Close in 10 seconds